Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVGR NASDAQ:BLAC NASDAQ:ICU NASDAQ:QNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$0.47$0.47$0.36▼$1.93$1.57M1.291.44 million shsN/ABLACBellevue Life Sciences Acquisition$1.00-4.8%$1.31$3.01▼$13.40$4.04M-0.0822,330 shs131,822 shsICUSeaStar Medical$0.71+6.7%$0.92$0.31▼$9.56$7.45M-1.091.78 million shs1.51 million shsQNRXQuoin Pharmaceuticals$8.48-3.0%$8.66$5.01▼$54.95$5.14M1.47137,282 shs3,067 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger0.00%0.00%0.00%0.00%-72.12%BLACBellevue Life Sciences Acquisition0.00%-4.84%-22.88%-11.28%-89.07%ICUSeaStar Medical+9.14%+8.31%-31.52%-46.81%-91.44%QNRXQuoin Pharmaceuticals-0.23%-2.73%+4.86%+59.49%-62.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVGRAvingerN/AN/AN/AN/AN/AN/AN/AN/ABLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AICUSeaStar Medical0.4788 of 5 stars0.02.00.00.03.01.70.0QNRXQuoin Pharmaceuticals1.475 of 5 stars0.05.00.00.02.70.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVGRAvinger 0.00N/AN/AN/ABLACBellevue Life Sciences Acquisition 0.00N/AN/AN/AICUSeaStar Medical 0.00N/AN/AN/AQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVGRAvinger$7.65M0.21N/AN/A($4.53) per share-0.10BLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/AN/AICUSeaStar Medical$140K56.78N/AN/A($0.34) per share-2.09QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$35.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVGRAvinger-$18.32M-$11.06N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)BLACBellevue Life Sciences AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AICUSeaStar Medical-$24.83M-$3.47N/A∞N/AN/AN/A-313.28%8/12/2025 (Estimated)QNRXQuoin Pharmaceuticals-$8.96M-$48.81N/AN/AN/AN/A-148.97%-77.23%8/14/2025 (Estimated)Latest AVGR, ICU, BLAC, and QNRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025QNRXQuoin Pharmaceuticals-$6.83N/AN/AN/AN/AN/A5/14/2025Q1 2025ICUSeaStar Medical-$0.52-$0.44+$0.08-$0.44$0.15 million$0.29 million5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$3.85-$6.50-$2.65-$6.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVGRAvingerN/AN/AN/AN/AN/ABLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/AICUSeaStar MedicalN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVGRAvingerN/AN/AN/ABLACBellevue Life Sciences AcquisitionN/AN/AN/AICUSeaStar MedicalN/A0.960.96QNRXQuoin PharmaceuticalsN/A2.572.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVGRAvinger18.30%BLACBellevue Life Sciences Acquisition55.30%ICUSeaStar Medical1.69%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipAVGRAvinger42.80%BLACBellevue Life Sciences Acquisition33.67%ICUSeaStar Medical1.30%QNRXQuoin Pharmaceuticals3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVGRAvinger703.31 million1.89 millionNot OptionableBLACBellevue Life Sciences AcquisitionN/A4.04 million2.68 millionNot OptionableICUSeaStar Medical211.20 million11.06 millionNot OptionableQNRXQuoin Pharmaceuticals4590,000566,000Not OptionableAVGR, ICU, BLAC, and QNRX HeadlinesRecent News About These CompaniesQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases - MorningstarJune 27, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New Episode of NETHERTON NOW Featuring Expert Insights on Netherton Syndrome - NasdaqJune 27, 2025 | nasdaq.comQNRX - Quoin Pharmaceuticals Ltd ADR Executives - MorningstarJune 26, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin DiseasesJune 26, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome - Yahoo FinanceJune 25, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton SyndromeJune 24, 2025 | tmcnet.comQuoin Pharmaceuticals, Ltd. (QNRX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comQNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand FurtherMay 29, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical StudyMay 22, 2025 | manilatimes.netMQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton SyndromeMay 20, 2025 | globenewswire.comQuoin reports progress in pediatric skin disorder studyMay 15, 2025 | investing.comQuoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyMay 14, 2025 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial ResultsMay 14, 2025 | manilatimes.netMA Peek at Quoin Pharmaceuticals's Future EarningsMay 12, 2025 | benzinga.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleMay 1, 2025 | finanznachrichten.deQuoin Pharmaceuticals regains Nasdaq compliance with bid priceMay 1, 2025 | investing.comQuoin Pharmaceuticals regains Nasdaq complianceApril 30, 2025 | msn.comQuoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleApril 30, 2025 | globenewswire.comWhy Quoin Pharmaceuticals, Ltd.’s (QNRX) Stock Is Down 13.50%April 10, 2025 | aaii.comAQuoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaignApril 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVGR, ICU, BLAC, and QNRX Company DescriptionsAvinger NASDAQ:AVGR$0.47 0.00 (0.00%) As of 07/1/2025Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.Bellevue Life Sciences Acquisition NASDAQ:BLAC$1.00 -0.05 (-4.76%) As of 07/17/2025Bellevue Life Sciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.SeaStar Medical NASDAQ:ICU$0.71 +0.04 (+6.74%) Closing price 04:00 PM EasternExtended Trading$0.68 -0.03 (-4.18%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.Quoin Pharmaceuticals NASDAQ:QNRX$8.48 -0.26 (-2.97%) Closing price 03:59 PM EasternExtended Trading$8.54 +0.06 (+0.71%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
